What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million
This disposition was tied to vesting of performance-based RSUs at 83% of the target.
Overview
David Thomson, EVP General Counsel & Secretary of MannKind Corporation (NASDAQ:MNKD), reported a sale of 123,000 shares of common stock between July 15 and July 17, 2026, according to a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($4.08); post-transaction value based on July 17, 2026 market close ($4.03).
Details
MannKind Corporation is a biopharmaceutical company with a market capitalization of $1.2 billion, operating from its Danbury headquarters. The company's strategic focus centers on respiratory-delivered treatments for endocrine and rare pulmonary disorders, with Afrezza representing its core commercial asset. Despite current net losses, MannKind's TTM revenue of $360.80 million reflects its established market presence and ongoing commercialization efforts in specialized therapeutic areas.
Source
Originally published at www.fool.com.